

Product Information

SARS-CoV Virus-like Particles (SARS VLPs)-S/M/E

Cat. No.: **VLP-042YF**

This product is for research use only and is not intended for diagnostic use.

Recombinant SARS-CoV Virus-like Particles (SARS VLPs) are produced in insect SF21 cells, assembled with S, M and E proteins. VLP is mimicking the native 3D structure of viruses which can elicit strong immune responses. However, VLPs lack viral genomic material which makes them non-infectious, unable to replicate and enhance the safety during manufacture and administration. SARS VLPs can be used in the development of SARS diagnostics and in vaccine development and R&D (including use as an immunogen).

Product Specifications

Structural Proteins

Spike protein (S), Membrane protein (M) and Envelope protein (E)

Expression Systems

Insect cell (Sf21) expression system

Form

Liquid

Alternative Names

Severe acute respiratory syndrome coronavirus; SARS-CoV; SARS-CoV Virus; Virus-like particles; SARS Virus-like particles; SARS VLP

Storage

Store at 4°C short term (2-4 weeks). Store at -80 °C long term. Avoid repeated freeze/thaw cycles.

Virus Background

Virus Family

Coronaviridae

Virus Species

SARS

Virus Overview

SARS-CoV is a positive-sense single-stranded RNA virus (and hence Baltimore class IV) that is contagious in humans. The virus caused the 2002-2004 SARS outbreak. It is believed to have zoonotic origins and has close genetic similarity to bat coronaviruses, suggesting it emerged from a bat-borne virus. The virus primarily spreads between people through close contact and via respiratory droplets produced from coughs or sneezes. It mainly enters human cells by binding to the angiotensin converting enzyme 2 (ACE2).

Virus Structure

Enveloped, positive-sense, single-stranded RNA virus

Related Disease

Severe acute respiratory syndrome, SARS